Log In
Print
BCIQ
Print
Print this Print this
 

SMT 19969, SMT19969

  Manage Alerts
Collapse Summary General Information
Company Summit Corp. plc
DescriptionOral, small molecule, heterocyclic antibiotic
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI); Treat Clostridium difficile-associated diarrhea (CDAD)
Regulatory Designation

U.S. - Qualified Infectious Disease Program (Treat Clostridium difficile infection (CDI))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today